Back to Search Start Over

The application of nanoparticles in cancer immunotherapy: Targeting tumor microenvironment

Authors :
Xianqun Fan
Jipeng Li
Muyue Yang
Ping Gu
Source :
Bioactive Materials, Bioactive Materials, Vol 6, Iss 7, Pp 1973-1987 (2021)
Publication Year :
2021
Publisher :
Elsevier BV, 2021.

Abstract

The tumor development and metastasis are closely related to the structure and function of the tumor microenvironment (TME). Recently, TME modulation strategies have attracted much attention in cancer immunotherapy. Despite the preliminary success of immunotherapeutic agents, their therapeutic effects have been restricted by the limited retention time of drugs in TME. Compared with traditional delivery systems, nanoparticles with unique physical properties and elaborate design can efficiently penetrate TME and specifically deliver to the major components in TME. In this review, we briefly introduce the substitutes of TME including dendritic cells, macrophages, fibroblasts, tumor vasculature, tumor-draining lymph nodes and hypoxic state, then review various nanoparticles targeting these components and their applications in tumor therapy. In addition, nanoparticles could be combined with other therapies, including chemotherapy, radiotherapy, and photodynamic therapy, however, the nanoplatform delivery system may not be effective in all types of tumors due to the heterogeneity of different tumors and individuals. The changes of TME at various stages during tumor development are required to be further elucidated so that more individualized nanoplatforms could be designed.<br />Graphical abstract Image 1<br />Highlights • In responsive to the changes in TME, nanoparticles target tumor microenvironment and enhance the therapeutic effect. • Nanoparticles modulate the activation and maturation of DC. • Nanoparticles could reprogram polarization of TAM and relieve hypoxia. • Nanoparticles could transfer the immunosuppressive TME to immunosupportive.

Subjects

Subjects :
MDSCs, myeloid-derived suppressor cells
medicine.medical_treatment
PLGA, poly(lactic-co-glycolic acid)
Cancer immunotherapy
BTK, Bruton's tyrosine kinase
02 engineering and technology
CAFs, cancer associated fibroblasts
CCL, chemoattractant chemokines ligand
DSF/Cu, disulfiram/copper
melittin-NP, melittin-lipid nanoparticle
IFN-γ, interferon-γ
TNF-α, tumor necrosis factor alpha
ANG2, angiopoietin-2
Hypoxia
lcsh:QH301-705.5
cDCs, conventional dendritic cells
TME, tumor microenvironment
DMXAA, 5,6-dimethylxanthenone-4-acetic acid
HB-GFs, heparin-binding growth factors
M2NP, M2-like TAM dual-targeting nanoparticle
ECM, extracellular matrix
IFP, interstitial fluid pressure
HIF, hypoxia-inducible factor
Tumor microenvironment
PDT, photodynamic therapy
Tregs, regulatory T cells
tdLNs, tumor-draining lymph nodes
0210 nano-technology
Ab, antibodies
BBB, blood-brain barrier
DMMA, 2,3-dimethylmaleic anhydrid
SA, sialic acid
FDA, the Food and Drug Administration
PS, photosensitizer
Biomedical Engineering
Ag, antigen
Article
PD-1, programmed cell death protein 1
Biomaterials
TAMs, tumor-associated macrophages
lcsh:TA401-492
FAP, fibroblast activation protein
EPR, enhanced permeability and retention
NPs, nanoparticles
MPs, microparticles
NO, nitric oxide
Tumor therapy
scFv, single-chain variable fragment
medicine.disease
IL, interleukin
Radiation therapy
siRNA, small interfering RNA
Nanoparticles
TDPA, tumor-derived protein antigens
lcsh:Materials of engineering and construction. Mechanics of materials
HSA, human serum albumin
RLX, relaxin-2
Bcl-2, B-cell lymphoma 2
PSCs, pancreatic stellate cells
VDA, vasculature disrupting agent
Photodynamic therapy
CaCO3, calcium carbonate
Metastasis
AuNCs, gold nanocages
CTLA4, cytotoxic lymphocyte antigen 4
HPMA, N-(2-hydroxypropyl) methacrylamide
HA, hyaluronic acid
TIM-3, T cell immunoglobulin domain and mucin domain-3
TGF-β, transforming growth factor β
UPS-NP, ultra-pH-sensitive nanoparticle
IBR, Ibrutinib
MCMC, mannosylated carboxymethyl chitosan
α-SMA, alpha-smooth muscle actin
021001 nanoscience & nanotechnology
VEGF, vascular endothelial growth factor
TAAs, tumor-associated antigens
LPS, lipopolysaccharide
APCs, antigen-presenting cells
Delivery system
DCs, dendritic cells
NF-κB, nuclear factor κB
PHDs, prolyl hydroxylases
EMT, epithelial-mesenchymal transition
TLR, Toll-like receptor
Biotechnology
PFC, perfluorocarbon
0206 medical engineering
CAP, cleavable amphiphilic peptide
SPARC, secreted protein acidic and rich in cysteine
TfR, transferrin receptor
CTL, cytotoxic T lymphocytes
ODN, oligodeoxynucleotides
nMOFs, nanoscale metal-organic frameworks
ROS, reactive oxygen species
AuNPs, gold nanoparticles
medicine
EPG, egg phosphatidylglycerol
CAR-T, Chimeric antigen receptor-modified T-cell therapy
Chemotherapy
business.industry
AC-NPs, antigen-capturing nanoparticles
TIE2, tyrosine kinase with immunoglobulin and epidermal growth factor homology domain 2
020601 biomedical engineering
EGFR, epidermal growth factor receptor
LMWH, low molecular weight heparin
PTX, paclitaxel
lcsh:Biology (General)
Cancer research
MnO2, manganese dioxide
NK, nature killer
sense organs
business
RBC, red-blood-cell

Details

ISSN :
2452199X
Volume :
6
Database :
OpenAIRE
Journal :
Bioactive Materials
Accession number :
edsair.doi.dedup.....3d9e3a12774af1e45fb188f205ad9bdc